Sun Pharma Advanced Research Co (NSE:SPARC) Long-Term Debt: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
62 GF Score
Price ₹259.42
GF Value ₹4,528.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Long-Term Debt?

Sun Pharma Advanced Research Co NSE:SPARC -1.96% 62 Long-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 62/100 and a GF Value™ of ₹4,528.34 (Possible Value Trap). The stock has 7 warning signs investors should review.

Sun Pharma Advanced Research Co's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹0 Mil.

Sun Pharma Advanced Research Co's quarterly Long-Term Debt declined from Sep. 2025 (₹1,000 Mil) to Dec. 2025 (₹0 Mil) but then stayed the same from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Sun Pharma Advanced Research Co's annual Long-Term Debt increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹1,000 Mil) but then declined from Mar. 2025 (₹1,000 Mil) to Mar. 2026 (₹0 Mil).

Sun Pharma Advanced Research Co  (NSE:SPARC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sun Pharma Advanced Research Co Long-Term Debt Related Terms

Sun Pharma Advanced Research Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Long-Term Debt Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1,000.00 0.00

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,000.00 0.00 1,000.00 0.00 0.00
NSE:SPARC
62GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Long-Term Debt of ₹0 Mil as of Mar. 2026.
Is Sun Pharma Advanced Research Co's Long-Term Debt too high?
Sun Pharma Advanced Research Co's current Long-Term Debt is ₹0 Mil. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Long-Term Debt compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sun Pharma Advanced Research Co's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,528.34, compared to a current price of ₹259.42 — trading 94.3% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Sun Pharma Advanced Research Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Long-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹259.42 is trading 94.3% below its estimated GF Value™ of ₹4,528.34. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹4,528.34 vs. price of ₹259.42 (94.3% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
62GF Score

Get the complete analysis for NSE:SPARC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹259.42
Price
₹4,528.34
GF Value